Mural Oncology (NASDAQ:MURA) Rating Lowered to Outperform at Raymond James

Mural Oncology (NASDAQ:MURA) was downgraded by stock analysts at Raymond James from a “strong-buy” rating to an “outperform” rating in a report issued on Tuesday, Marketbeat Ratings reports. They currently have a $18.00 target price on the stock.

Other equities research analysts also recently issued research reports about the stock. HC Wainwright reissued a “buy” rating and issued a $18.00 target price on shares of Mural Oncology in a research report on Wednesday, March 12th. Jones Trading reiterated a “hold” rating on shares of Mural Oncology in a research note on Tuesday. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $13.00.

Mural Oncology Stock Performance

Shares of MURA opened at $1.33 on Tuesday. Mural Oncology has a one year low of $1.30 and a one year high of $5.12. The stock has a 50-day moving average price of $3.82 and a 200 day moving average price of $3.60. The company has a market capitalization of $22.91 million, a P/E ratio of -0.15 and a beta of 3.66.

Mural Oncology (NASDAQ:MURA) last released its quarterly earnings results on Tuesday, March 11th. The company reported ($2.01) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.96) by ($0.05). During the same period last year, the business earned ($3.57) EPS. As a group, equities research analysts forecast that Mural Oncology will post -7.54 earnings per share for the current fiscal year.

Institutional Trading of Mural Oncology

Institutional investors and hedge funds have recently modified their holdings of the business. Commerce Bank bought a new stake in shares of Mural Oncology during the 3rd quarter valued at about $39,000. FMR LLC raised its position in shares of Mural Oncology by 124.7% during the 3rd quarter. FMR LLC now owns 20,580 shares of the company’s stock worth $64,000 after purchasing an additional 11,423 shares during the period. Jane Street Group LLC bought a new stake in shares of Mural Oncology in the 4th quarter worth approximately $68,000. Two Sigma Advisers LP bought a new position in Mural Oncology during the 4th quarter worth $84,000. Finally, Bridgeway Capital Management LLC acquired a new stake in Mural Oncology in the fourth quarter worth $94,000. 80.21% of the stock is owned by institutional investors and hedge funds.

Mural Oncology Company Profile

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.